Andris H Ellims1, Gerard Wong2, Jacquelyn M Weir2, Philip Lew3, Peter J Meikle4, Andrew J Taylor1. 1. Heart Centre, Alfred Hospital, Commercial Road, Melbourne, VIC 3004, Australia Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia. 2. Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia. 3. Department of Radiology, Alfred Hospital, Melbourne, Australia. 4. Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia peter.meikle@bakeridi.edu.au.
Abstract
AIMS: The optimal management of asymptomatic subjects at intermediate risk of coronary artery disease (CAD) is often uncertain. Re-stratification to a high- or low-risk category may enable optimization of preventative strategies. Coronary computed tomographic angiography (CCTA) enables a minimally invasive assessment of coronary artery plaque quantity and composition. Non-calcified plaque by CCTA is lipid-rich and more vulnerable to rupture and resultant acute coronary syndromes. The purpose of this study was to determine whether novel approaches to CAD risk stratification, such as plasma lipid profiling, may predict non-calcified plaque burden in intermediate risk subjects. METHODS AND RESULTS: CCTA and several markers of CAD (including plasma lipid profiling, carotid intima-media thickness, aortic pulse wave velocity, and high-sensitivity C-reactive protein) were prospectively performed in 100 asymptomatic patients at intermediate CAD risk according to the Framingham risk score. Segment stenosis scores (SSS) were calculated to evaluate the burden of total, calcified, and non-calcified coronary artery plaque. Non-calcified plaque was observed in 66 subjects and 158 (11%) of 1425 coronary artery segments. Eighteen lipid species demonstrated significant associations with non-calcified plaque burden, but not with total plaque or calcified plaque burden. No other marker of CAD was found to predict coronary artery plaque burden. CONCLUSIONS: Plasma lipidomic analysis can predict the burden of non-calcified coronary plaque in asymptomatic subjects at intermediate risk of CAD. Re-stratification of these patients by plasma lipid profiling may enable more appropriate and effective primary prevention management strategies. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The optimal management of asymptomatic subjects at intermediate risk of coronary artery disease (CAD) is often uncertain. Re-stratification to a high- or low-risk category may enable optimization of preventative strategies. Coronary computed tomographic angiography (CCTA) enables a minimally invasive assessment of coronary artery plaque quantity and composition. Non-calcified plaque by CCTA is lipid-rich and more vulnerable to rupture and resultant acute coronary syndromes. The purpose of this study was to determine whether novel approaches to CAD risk stratification, such as plasma lipid profiling, may predict non-calcified plaque burden in intermediate risk subjects. METHODS AND RESULTS:CCTA and several markers of CAD (including plasma lipid profiling, carotid intima-media thickness, aortic pulse wave velocity, and high-sensitivity C-reactive protein) were prospectively performed in 100 asymptomatic patients at intermediate CAD risk according to the Framingham risk score. Segment stenosis scores (SSS) were calculated to evaluate the burden of total, calcified, and non-calcified coronary artery plaque. Non-calcified plaque was observed in 66 subjects and 158 (11%) of 1425 coronary artery segments. Eighteen lipid species demonstrated significant associations with non-calcified plaque burden, but not with total plaque or calcified plaque burden. No other marker of CAD was found to predict coronary artery plaque burden. CONCLUSIONS: Plasma lipidomic analysis can predict the burden of non-calcified coronary plaque in asymptomatic subjects at intermediate risk of CAD. Re-stratification of these patients by plasma lipid profiling may enable more appropriate and effective primary prevention management strategies. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Lindsay T Fourman; Charles F Saylor; Lediya Cheru; Kathleen Fitch; Sara Looby; Kiana Keller; Jake A Robinson; Udo Hoffmann; Michael T Lu; Tricia Burdo; Janet Lo Journal: J Infect Dis Date: 2020-02-03 Impact factor: 5.226
Authors: Ruth R Magaye; Feby Savira; Yue Hua; Darren J Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H Wang Journal: Cell Mol Life Sci Date: 2018-12-06 Impact factor: 9.261
Authors: Jennifer Jao; Lauren C Balmert; Shan Sun; Grace A McComsey; Todd T Brown; Phyllis C Tien; Judith S Currier; James H Stein; Yunping Qiu; Derek LeRoith; Irwin J Kurland Journal: J Clin Endocrinol Metab Date: 2022-01-01 Impact factor: 6.134
Authors: Aline M A Martins; Mariana U B Paiva; Diego V N Paiva; Raphaela M de Oliveira; Henrique L Machado; Leonardo J S R Alves; Carolina R C Picossi; Andréa T Faccio; Marina F M Tavares; Coral Barbas; Viviane Z R Giraldez; Raul D Santos; Guilherme U Monte; Fernando A Atik Journal: Front Cardiovasc Med Date: 2021-12-22
Authors: Sock Hwee Tan; Hiromi W L Koh; Jing Yi Chua; Bo Burla; Ching Ching Ong; Li San Lynette Teo; Xiaoxun Yang; Peter I Benke; Hyungwon Choi; Federico Torta; A Mark Richards; Markus R Wenk; Mark Y Chan Journal: Arterioscler Thromb Vasc Biol Date: 2021-11-23 Impact factor: 8.311
Authors: Elena Michelucci; Nicoletta Di Giorgi; Francesco Finamore; Jeff M Smit; Arthur J H A Scholte; Giovanni Signore; Silvia Rocchiccioli Journal: Sci Rep Date: 2021-06-18 Impact factor: 4.379
Authors: Antonella Bodini; Elena Michelucci; Nicoletta Di Giorgi; Chiara Caselli; Giovanni Signore; Danilo Neglia; Jeff M Smit; Arthur J H A Scholte; Pierpaolo Mincarone; Carlo G Leo; Gualtiero Pelosi; Silvia Rocchiccioli Journal: Front Cardiovasc Med Date: 2021-07-16